Efficacy on prophylactic topical steroid for rash in patients treated eith Erlotinib

Not Applicable

• Conditions: on-Small Cell Lung Cancer

• Registration Number: JPRN-UMIN000032172
• Lead Sponsor: Showa University Northern Yokohama Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with superior vena caval syndrome 2)Patients with compressive spinal cord lesion 3)History of hypersensitivity for drugs 4)Patients with brain metastasis or anticonvulsant medication 5)Patients with severe skin disease or treated by steroid 6)Patients with idiopathic pulomary fibrosis,pneumoconiosis,other interstitial pneumonia,idiopathic pulmonary,drug induced pulmonary damage or lungs inflammation 7)Interval from precious treatment,of following,at enrollment a)Equal or more than 4 weeks after b)Equal or more than 2 weeks after 8)active fluid in the abdomen or pleural effusion 9)Other clinically significant complications 10)Clinically significant eye diseases 11)Patients with diverticulitis 12)History of perforation of the digestive tract within one years 13)Other clinically significant cardiac disease 14)Other clinically significant psychiatric disease 15)Pregnancy,breast feeding and suspecterd pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified